Story

Sionna Therapeutics Stock Plummets 92% After Cystic Fibrosis Drug Fails Mid-Stage Trial

ENTHMSVIIDZHZH-TWJAKOHI
Aug 10, 20262 min read
Sionna Therapeutics Stock Plummets 92% After Cystic Fibrosis Drug Fails Mid-Stage Trial
Text size
Background

Shares of Sionna Therapeutics collapsed by more than 92% in morning trading after the company announced its lead cystic fibrosis drug candidate, SION-719, failed to show any meaningful benefit in a Phase 2a clinical trial. The company confirmed it will not advance the development of the drug as an add-on to the current standard of care.

Clinical Trial Failure

Topline data from the PreciSION CF study showed that SION-719, when added to Vertex Pharmaceuticals' market-leading drug Trikafta, did not significantly improve CFTR protein function. The primary endpoint, a measure of sweat chloride concentration, showed a placebo-adjusted change of just -1.0 mmol/L, a result the company described as statistically indistinguishable from placebo.

Analysts had widely considered a reduction of at least 10 mmol/L to be a conservative benchmark for success. The trial was a randomized, double-blind, placebo-controlled crossover study involving 15 patients with cystic fibrosis.

Market Reaction and Analyst Downgrades

The clinical failure prompted a severe market sell-off and swift action from Wall Street analysts. The stock hit a new 52-week low of $4.01 as investors rapidly reassessed the company's prospects.

Key analyst actions included:

Sample IUX Markets – In-articleAd
  • Wedbush: Downgraded Sionna from Outperform to Neutral and slashed its price target from $53 to $5.
  • Stifel: Cut its rating from Buy to Hold and reduced its price target from $55 to $7, calling the outcome an "unequivocal failure."

In contrast, shares of competitor Vertex Pharmaceuticals (VRTX) rose on the news. The failure of SION-719 removes a potential near-term competitive threat to its dominant Trikafta franchise in the cystic fibrosis market.

Company Outlook

With its lead asset now shelved, investor focus shifts to Sionna's earlier-stage programs, particularly the SION-451 dual combination therapy. However, meaningful clinical data from this program is not expected for a considerable time.

Sionna reported ending the second quarter with approximately $268.3 million in cash and equivalents. The company announced it plans to preserve capital while it evaluates the next steps for its remaining pipeline.

Read next

More on Stocks
Back to latest news

LATEST